CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Managing Side Effects with South Asian Foods July 19, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+... October 22, 2020 UK sunburn risk: Third of adults more likely to protect their... August 2, 2021 Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... November 21, 2020 Load more HOT NEWS ¿Puede el uso de aceites esenciales ayudar a tratar el cáncer... When Caregiving Takes a Toll FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction...
